MX2023002741A - Células madre mesenquimales que coexpresan cxcr4 e il -10 y usos de las mismas. - Google Patents

Células madre mesenquimales que coexpresan cxcr4 e il -10 y usos de las mismas.

Info

Publication number
MX2023002741A
MX2023002741A MX2023002741A MX2023002741A MX2023002741A MX 2023002741 A MX2023002741 A MX 2023002741A MX 2023002741 A MX2023002741 A MX 2023002741A MX 2023002741 A MX2023002741 A MX 2023002741A MX 2023002741 A MX2023002741 A MX 2023002741A
Authority
MX
Mexico
Prior art keywords
stem cells
mesenchymal stem
expressing cxcr4
mscs
cxcr4
Prior art date
Application number
MX2023002741A
Other languages
English (en)
Spanish (es)
Inventor
García María Fernández
Roncero Juan Antonio Bueren
Rosario Hervás-Salcedo
Damián García-Olmo
Mariano García-Arranz
Rodríguez Miriam Hernando
González Rosa María Yáñez
Santalla Mercedes López
Ferreira Marina Inmaculada Garin
Original Assignee
Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz filed Critical Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz
Publication of MX2023002741A publication Critical patent/MX2023002741A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2023002741A 2020-09-07 2021-09-07 Células madre mesenquimales que coexpresan cxcr4 e il -10 y usos de las mismas. MX2023002741A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382792.8A EP3964265A1 (en) 2020-09-07 2020-09-07 Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof
PCT/EP2021/074612 WO2022049306A1 (en) 2020-09-07 2021-09-07 Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof

Publications (1)

Publication Number Publication Date
MX2023002741A true MX2023002741A (es) 2023-05-26

Family

ID=72473480

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002741A MX2023002741A (es) 2020-09-07 2021-09-07 Células madre mesenquimales que coexpresan cxcr4 e il -10 y usos de las mismas.

Country Status (11)

Country Link
US (1) US20230398152A1 (https=)
EP (2) EP3964265A1 (https=)
JP (1) JP2023540599A (https=)
KR (1) KR20230082622A (https=)
CN (1) CN116507733A (https=)
AU (1) AU2021337798A1 (https=)
BR (1) BR112023004167A2 (https=)
CA (1) CA3194344A1 (https=)
MX (1) MX2023002741A (https=)
SA (1) SA523442866B1 (https=)
WO (1) WO2022049306A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
CN115927178A (zh) * 2022-11-17 2023-04-07 华夏源(上海)生物科技有限公司 一种检测间充质干细胞抑制b细胞分化为浆细胞的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065396A1 (en) * 1996-08-30 2009-06-03 Human Genome Sciences, Inc. Interleukin-19
US20090074733A1 (en) * 2005-12-09 2009-03-19 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
CA2784861A1 (en) * 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
PL3242933T3 (pl) * 2015-01-08 2019-08-30 Apceth Gmbh & Co. Kg Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat)
JP7086928B2 (ja) * 2016-07-25 2022-06-20 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変されたナチュラルキラー細胞を生成する方法および使用方法
AU2019291069B2 (en) * 2018-06-19 2026-02-19 Fondazione Centro San Raffaele Production of engineered dendritic cells and uses thereof

Also Published As

Publication number Publication date
BR112023004167A2 (pt) 2023-05-09
SA523442866B1 (ar) 2024-05-05
WO2022049306A1 (en) 2022-03-10
CA3194344A1 (en) 2022-03-10
CN116507733A (zh) 2023-07-28
AU2021337798A1 (en) 2023-05-18
US20230398152A1 (en) 2023-12-14
JP2023540599A (ja) 2023-09-25
KR20230082622A (ko) 2023-06-08
EP4210834A1 (en) 2023-07-19
EP3964265A1 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
SA523442866B1 (ar) خلايا جذعية وسيطية تشارك في التعبير عن واستخداماتها cxcr4 وil-10
Han et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases
Magatti et al. The immunomodulatory properties of amniotic cells: the two sides of the coin
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
Casiraghi et al. Mesenchymal stromal cells to promote solid organ transplantation tolerance
Li et al. Interactions between mesenchymal stem cells and the immune system
Ansboro et al. Mesenchymal stem cells for the management of rheumatoid arthritis: immune modulation, repair or both?
Zheng et al. Mesenchymal stromal cells affect disease outcomes via macrophage polarization
de Oliveira Bravo et al. Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression
English et al. Mesenchymal stromal cells: facilitators of successful transplantation?
Machado et al. Immunological characteristics of mesenchymal stem cells
CO2019013001A2 (es) Proteínas de anticuerpo injertadas con citocina y métodos de uso en el tratamiento del cáncer
Peltzer et al. Mesenchymal stromal cells based therapy in systemic sclerosis: rational and challenges
MY155137A (en) Compounds that expand hematopoietic stem cells
WO2021092581A9 (en) Generation of engineered regulatory t cells
Cheng et al. The impact of mesenchymal stem cell source on proliferation, differentiation, immunomodulation and therapeutic efficacy
Mohanty et al. Immunomodulatory properties of bone marrow mesenchymal stem cells: Aparna Mohanty et al.
Franquesa et al. The impact of mesenchymal stem cell therapy in transplant rejection and tolerance
EA201790025A1 (ru) Создание банка мезенхимальных стромальных клеток из объединенных мононуклеарных клеток нескольких доноров костного мозга
RU2013141914A (ru) Лечение амиотрофического бокового склероза с использованием полученных из пуповины клеток
WO2019098759A3 (ko) 형질전환된 인간세포 및 이의 용도
Cruz et al. Prospects and progress in cell therapy for acute respiratory distress syndrome
WO2019067951A3 (en) Cd1d and tcr-nkt cells
WO2019113375A3 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
Jin et al. Next generation of neurological therapeutics: Native and bioengineered extracellular vesicles derived from stem cells